Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Conditions: Metastatic Breast Cancer; Breast Cancer Interventions: Drug: Neratinib; Drug: Capmatinib Sponsors: M.D. Anderson Cancer Center; Celcuity, Inc.; Novartis; Puma Biotechnology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Inflammatory Breast Cancer | Research